OSR (NASDAQ:OSRH) Shares Climb 1.3% – Still a Buy?

Shares of OSR Holdings, Inc. (NASDAQ:OSRH) were up 1.3% on Tuesday. The company traded as high as $0.2350 and last traded at $0.2076. 232,501 shares traded hands during trading, a decline of 96% from the average daily volume of 6,002,917 shares. The stock had previously closed at $0.2050.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of OSR in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

OSR Stock Up 1.3%

The firm has a 50-day moving average of $0.31 and a 200 day moving average of $0.41. The stock has a market capitalization of $7.29 million, a P/E ratio of -0.56 and a beta of 0.49.

OSR (NASDAQ:OSRH) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter. OSR had a negative net margin of 593.15% and a negative return on equity of 8.36%. The business had revenue of $0.32 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in OSR stock. Citadel Advisors LLC acquired a new stake in shares of OSR Holdings, Inc. (NASDAQ:OSRH) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,810 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned approximately 0.36% of OSR at the end of the most recent quarter. Hedge funds and other institutional investors own 55.30% of the company’s stock.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.